Posts
February 18 2024
Revelation Biosciences, Inc. announced the closing of its Public Offering in the amount of $6,200,000. EG&S acted as counsel to the Placement Agent.
February 17 2024
Draganfly Inc. announced the closing of its Underwritten Public Offering in the amount of $3,600,000. EG&S acted as counsel to the Underwriter.
February 16 2024
Ohmyhome Ltd., a one-stop-shop property technology platform providing end-to-end property solutions and services to buy, sell, rent, and renovate homes, as well as property management services for condominiums in Singapore, announced the closing of its upsized public offering in the amount of $4,800,000. EGS acted as counsel to Maxim Group LLC, the sole placement agent in connection with this offering.
February 15 2024
Evaxion Biotech A/S announced the closing of its Public Offering in the amount of $15,000,000. EG&S acted as counsel to the Placement Agent.
February 15 2024
Evaxion Biotech A/S announced the closing of its Public Offering in the amount of $15,000,000. EG&S acted as counsel to the Placement Agent.
February 14 2024
CERo Therapeutics, Inc., an immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announced the closing of its business combination with Phoenix Biotech Acquisition Corp. The transaction is valued at approximately $50,000,000. EGS acted as counsel to CERo Therapeutics, Inc.
February 14 2024
Aprea Therapeutics, Inc. announced the commencement of its At The Market Offering in the amount of $1,000,000. EG&S acted as counsel to the Sales Agent.
February 13 2024
FSD Pharma Inc. announced the commencement of its At The Market Offering in the amount of $11,930,350. EG&S acted as counsel to the Sales Agent.